BR112022016960A2 - Uso de análogos de ciclosporina para tratamento de câncer - Google Patents
Uso de análogos de ciclosporina para tratamento de câncerInfo
- Publication number
- BR112022016960A2 BR112022016960A2 BR112022016960A BR112022016960A BR112022016960A2 BR 112022016960 A2 BR112022016960 A2 BR 112022016960A2 BR 112022016960 A BR112022016960 A BR 112022016960A BR 112022016960 A BR112022016960 A BR 112022016960A BR 112022016960 A2 BR112022016960 A2 BR 112022016960A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer treatment
- cyclosporin analogs
- cancer
- treatment
- crv431
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
USO DE ANÁLOGOS DE CICLOSPORINA PARA TRATAMENTO DE CÂNCER. Trata-se de métodos, composições e kits adequados para uso na prevenção e tratamento de doenças proliferativas como câncer. Os métodos compreendem administrar a um indivíduo que precisa do mesmo uma composição que compreende um análogo de ciclosporina (por exemplo, CRV431), ou um sal, solvato, estereoisômero farmaceuticamente aceitável do mesmo. As composições e kits compreendem um análogo de ciclosporina (por exemplo, CRV431), ou um sal, solvato, estereoisômero farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062981383P | 2020-02-25 | 2020-02-25 | |
| PCT/US2021/019480 WO2021173723A1 (en) | 2020-02-25 | 2021-02-24 | Use of cyclosporine analogues for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022016960A2 true BR112022016960A2 (pt) | 2022-10-25 |
Family
ID=74885085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022016960A BR112022016960A2 (pt) | 2020-02-25 | 2021-02-24 | Uso de análogos de ciclosporina para tratamento de câncer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210269479A1 (pt) |
| EP (1) | EP4110346A1 (pt) |
| JP (1) | JP2023515569A (pt) |
| KR (1) | KR20220145849A (pt) |
| CN (1) | CN115484961A (pt) |
| AR (1) | AR121404A1 (pt) |
| AU (1) | AU2021227230A1 (pt) |
| BR (1) | BR112022016960A2 (pt) |
| CA (1) | CA3172368A1 (pt) |
| IL (1) | IL295498A (pt) |
| MX (1) | MX2022010454A (pt) |
| TW (1) | TW202140057A (pt) |
| WO (1) | WO2021173723A1 (pt) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2308149T3 (es) * | 2003-02-12 | 2008-12-01 | Biocompatibles Uk Limited | Composicion para la quimioemboloterapia de tumores solidos. |
| AU2011342284C1 (en) * | 2010-12-15 | 2017-07-13 | Contravir Pharmaceuticals, Inc. | Cyclosporine analogue molecules modified at amino acid 1 and 3 |
| ES2858517T3 (es) * | 2014-11-07 | 2021-09-30 | Sublimity Therapeutics Ltd | Composiciones que comprenden ciclosporina |
| CA3024320A1 (en) * | 2016-05-17 | 2017-11-23 | S&T Global Inc. | Novel cyclosporin derivatives and uses thereof |
| WO2018106928A1 (en) * | 2016-12-08 | 2018-06-14 | Contravir Pharmaceuticals, Inc. | Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3 |
| US20180296588A1 (en) * | 2017-04-14 | 2018-10-18 | Contravir Pharmaceuticals, Inc. | Combination therapy for treating viral infections |
| SI3886813T1 (sl) | 2018-11-26 | 2023-05-31 | Hepion Pharmaceuticals, Inc. | Farmacevtske formulacije analogov ciklosporina |
-
2021
- 2021-02-24 MX MX2022010454A patent/MX2022010454A/es unknown
- 2021-02-24 KR KR1020227031379A patent/KR20220145849A/ko unknown
- 2021-02-24 CN CN202180030754.XA patent/CN115484961A/zh active Pending
- 2021-02-24 WO PCT/US2021/019480 patent/WO2021173723A1/en active Application Filing
- 2021-02-24 IL IL295498A patent/IL295498A/en unknown
- 2021-02-24 JP JP2022551278A patent/JP2023515569A/ja active Pending
- 2021-02-24 AR ARP210100463A patent/AR121404A1/es unknown
- 2021-02-24 US US17/184,433 patent/US20210269479A1/en active Pending
- 2021-02-24 BR BR112022016960A patent/BR112022016960A2/pt unknown
- 2021-02-24 AU AU2021227230A patent/AU2021227230A1/en active Pending
- 2021-02-24 EP EP21712672.1A patent/EP4110346A1/en not_active Withdrawn
- 2021-02-24 TW TW110106469A patent/TW202140057A/zh unknown
- 2021-02-24 CA CA3172368A patent/CA3172368A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202140057A (zh) | 2021-11-01 |
| IL295498A (en) | 2022-10-01 |
| MX2022010454A (es) | 2022-09-19 |
| AU2021227230A1 (en) | 2022-09-08 |
| KR20220145849A (ko) | 2022-10-31 |
| WO2021173723A8 (en) | 2022-08-25 |
| US20210269479A1 (en) | 2021-09-02 |
| AR121404A1 (es) | 2022-06-01 |
| JP2023515569A (ja) | 2023-04-13 |
| CN115484961A (zh) | 2022-12-16 |
| WO2021173723A1 (en) | 2021-09-02 |
| EP4110346A1 (en) | 2023-01-04 |
| CA3172368A1 (en) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
| MX2019007587A (es) | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. | |
| BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
| BR112022002442A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| HN2011001593A (es) | Piridiloxi-indoles del vegf-r2 y uso de los mismos para el tratmiento de enfermedades | |
| CO2022001210A2 (es) | Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes | |
| BR112019017393A8 (pt) | Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico | |
| BR112016004358A8 (pt) | combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit | |
| BR112023006024A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| BR112022004397A2 (pt) | Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos | |
| BR112023001143A2 (pt) | Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo | |
| ECSP22040362A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
| CL2021000129A1 (es) | Apirasas solubilizadas, métodos y usos | |
| CO2020013834A2 (es) | Ciertos compuestos de pladienolida y métodos de uso | |
| BR112022016960A2 (pt) | Uso de análogos de ciclosporina para tratamento de câncer | |
| BR112022003867A8 (pt) | Conjugado anticorpo-droga (adc), composição farmacêutica e adc para seu uso ou composição para seu uso | |
| CO2023009085A2 (es) | Pauta posológica de levodopa | |
| BR112022016522A2 (pt) | Uso de análogos de ciclosporina para tratar fibrose | |
| DOP2021000028A (es) | Formulaciones de dendrímeros | |
| CL2021000627A1 (es) | Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular | |
| Kim et al. | Inhibitory effects of S-allylcysteine on cell proliferation of human cervical cancer cell line, HeLa | |
| BR112022012081A2 (pt) | Método para tratar câncer, kit, e, uso de uma combinação terapêutica | |
| UY39061A (es) | Inhibidores macrocíclicos de rip2-cinasa | |
| BR112021026561A2 (pt) | Uso de uma composição farmacêutica na fabricação de um medicamento para a prevenção ou tratamento de doença hepática |